12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Avastin bevacizumab: Phase III started

Genentech began the double-blind Phase III MERiDiAN (GO25632) trial to compare IV Avastin plus paclitaxel vs. placebo plus paclitaxel in about 480 HER2-negative patients with metastatic breast cancer. The trial will also evaluate VEGF-A as a predictive biomarker for efficacy with Avastin.

Last November, FDA Commissioner Margaret Hamburg revoked accelerated approval of Avastin in combination...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >